Pharmacokinetics and Pharmacodynamics Practice Questions

Q: A highly ionized drug is characterized by which of the following properties?

It is excreted mainly by the kidney.. **Explanation:** The pharmacokinetics of a drug are heavily influenced by its ionization state. According to the **pH partition hypothesis**, only non-ionized (lipid-soluble) drugs can easily cross biological membranes. **1. Why Option A is Correct:** Highly ionized drugs are **water-soluble (hydrophilic)** and polar. Because they are not lipid-soluble, they cannot easily diffuse back across the renal tubular epithelium into the systemic circulation (tubular reabsorption). Consequently, they remain trapped in the renal tubule and are **excreted mainly by the kidney**. **2. Why the Other Options are Incorrect:** * **Option B:** The placental barrier is a lipid membrane. Highly ionized drugs are lipid-insoluble and therefore **cannot cross the placenta** easily. * **Option C:** Absorption from the intestine requires crossing the lipid bilayer of mucosal cells. Ionized drugs have **poor oral bioavailability** because they cannot penetrate these membranes effectively. * **Option D:** Ionized drugs are lipophobic. They remain in the extracellular fluid or plasma and **do not accumulate in cellular lipids** or adipose tissue. **High-Yield Clinical Pearls for NEET-PG:** * **Ion Trapping:** This principle is used in toxicology. To hasten the excretion of an acidic drug (e.g., Aspirin), we **alkalinize the urine** (using Sodium Bicarbonate). This increases the ionization of the drug in the renal tubules, preventing reabsorption and increasing excretion. * **Blood-Brain Barrier (BBB):** Highly ionized drugs (like quaternary ammonium compounds, e.g., Neostigmine) cannot cross the BBB, whereas non-ionized drugs (e.g., Physostigmine) can. * **Rule of Thumb:** Lipid solubility $\propto$ Non-ionization $\propto$ Better absorption/distribution. Water solubility $\propto$ Ionization $\propto$ Better excretion.

Q: A volunteer is to receive a new drug in a phase I clinical trial. The clearance and the volume of distribution of the drug in the volunteer are 1.386 L/hr and 80 L respectively. What would be the approximate half-life of the drug?

40 hr. The half-life ($t_{1/2}$) of a drug is the time required for its plasma concentration to decrease by 50%. It is a critical pharmacokinetic parameter used to determine dosing intervals and the time required to reach a steady state. **1. Why Option C is Correct:** The relationship between half-life ($t_{1/2}$), Volume of Distribution ($V_d$), and Clearance ($CL$) is defined by the following formula [2]: $t_{1/2} = \frac{0.693 \times V_d}{CL}$ Given values: * $V_d = 80 \text{ L}$ * $CL = 1.386 \text{ L/hr}$ Calculation: $t_{1/2} = \frac{0.693 \times 80}{1.386}$ $t_{1/2} = \frac{55.44}{1.386} = 40 \text{ hours}$ **2. Why Other Options are Incorrect:** * **Option A (83 hr) & B (77 hr):** These values result from calculation errors, such as incorrectly multiplying the variables or using an incorrect constant instead of 0.693. * **Option D (0.02 hr):** This value is obtained if the formula is inverted (Clearance divided by Volume of Distribution), which is mathematically incorrect for calculating half-life. **Clinical Pearls for NEET-PG:** * **Steady State:** It takes approximately **4 to 5 half-lives** for a drug to reach a steady-state concentration ($C_{ss}$) during constant-rate infusion [3], [4]. * **Elimination:** Similarly, it takes about 4 to 5 half-lives for a drug to be effectively eliminated from the body after stopping the drug [3]. * **First-order Kinetics:** In first-order kinetics (most drugs), $t_{1/2}$ remains constant regardless of the dose [1]. In zero-order kinetics (e.g., high-dose Aspirin, Phenytoin, Ethanol), $t_{1/2}$ increases as the dose increases [1]. * **High-Yield Tip:** If you notice that $1.386$ is exactly $2 \times 0.693$, the calculation becomes much faster: $(0.693 \times 80) / (2 \times 0.693) = 80 / 2 = 40$.

Q: The redistribution phenomenon is observed in which of the following drugs?

Thiopentone. **Explanation:** **1. Why Thiopentone is Correct:** Redistribution is the process where a drug moves from its primary site of action (highly perfused organs like the brain) to other tissues (muscle and fat) to achieve equilibrium. **Thiopentone**, a highly lipid-soluble ultra-short-acting barbiturate, exemplifies this. After IV bolus administration, it rapidly enters the brain, causing immediate anesthesia. However, its action terminates within minutes—not because of metabolism, but because the drug **redistributes** from the brain into the skeletal muscles and eventually adipose tissue, lowering the plasma concentration and allowing the patient to wake up. **2. Why Other Options are Incorrect:** * **Halothane and Ether (Options A & B):** These are volatile inhalational anesthetics. Their duration of action is primarily governed by their **solubility in blood** (blood-gas partition coefficient) and elimination via exhalation, rather than redistribution. While some redistribution occurs with all lipid-soluble drugs, it is not the clinically defining mechanism for the termination of action for these gases as it is for Thiopentone. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Context:** Redistribution is a major factor in the termination of action for **highly lipid-soluble** drugs given intravenously in a single bolus. * **Other Examples:** Apart from Thiopentone, **Propofol** and **Fentanyl** also exhibit significant redistribution. * **Cumulative Effect:** If Thiopentone is given as repeated doses or a continuous infusion, the storage sites (muscle/fat) become saturated. In this scenario, the duration of action depends on hepatic metabolism rather than redistribution, leading to prolonged recovery (the "hangover" effect). * **Key Concept:** Redistribution increases the **volume of distribution (Vd)** of a drug over time.

Q: Which of the following statements about biotransformation is NOT true?

Conversion of polar to less polar compounds. **Explanation:** The primary goal of **biotransformation (metabolism)** is to facilitate the excretion of drugs from the body. To achieve this, the body converts **lipid-soluble (non-polar)** compounds into **water-soluble (polar)** compounds. Polar compounds are less likely to be reabsorbed in the renal tubules and are easily excreted in urine. Therefore, the statement that biotransformation converts polar to less polar compounds is **incorrect**. **Analysis of Options:** * **Option B (Correct Answer):** As stated, metabolism aims to increase polarity. Converting a polar drug into a less polar (lipid-soluble) one would lead to its reabsorption into the systemic circulation, defeating the purpose of excretion. * **Option A & D:** While metabolism often inactivates drugs, it can also generate **active metabolites** from active drugs (e.g., Diazepam to Oxazepam) or activate an inactive **prodrug** (e.g., Enalapril to Enalaprilat). * **Option C:** This is the fundamental principle of Phase I and Phase II reactions—increasing hydrophilicity to ensure the drug is "trapped" in the urine. **NEET-PG High-Yield Pearls:** * **Phase I Reactions:** Include Oxidation (most common), Reduction, and Hydrolysis. They introduce/unmask a functional group. * **Phase II Reactions:** Include Glucuronidation (most common), Acetylation, and Methylation. These are **true detoxification** steps that significantly increase polarity. * **Exception to Polarity:** In rare cases, metabolism can make a drug less soluble, such as the **acetylation of sulfonamides**, which can lead to crystalluria. * **Prodrug Example:** Levopa is converted to Dopamine; Prednisone is converted to Prednisolone.

Q: A 75 kg person is administered a drug with a half-life of 3 hours. What is the approximate clearance of the drug?

23 mL/min. ⚠️ **Note:** This question cannot be solved using standard pharmacokinetic formulas without the volume of distribution (Vd). The answer relies on estimation principles rather than exact calculation. ***23 mL/min*** - This represents a **low to moderate clearance** value, typical for drugs that undergo hepatic metabolism with low-to-intermediate extraction ratios - For context: Normal **creatinine clearance** (marker of GFR) is approximately 90-120 mL/min in adults [1], so 23 mL/min represents roughly 20-25% of renal clearance capacity - This is a plausible value for drugs with **predominantly hepatic metabolism** with low hepatic extraction ratio - Using the relationship $Cl = \frac{0.693 \times Vd}{t_{1/2}}$, this would correspond to a Vd of approximately 6 liters (if t½ = 3 hours) [2] *210 mL/min* - This represents **moderate to high clearance**, suggesting efficient elimination - Comparable to **renal plasma flow** (approximately 600-700 mL/min × filtration fraction) - Would require a Vd of approximately 54 liters with the given half-life - Typical for drugs with good renal excretion or intermediate hepatic extraction *1670 mL/min* - This is extremely high clearance, approaching **total hepatic blood flow** (1500 mL/min) - Would require Vd of approximately 433 liters, which exceeds total body water (42L in a 70kg person) - Only seen with high extraction ratio drugs (>0.7) with extensive first-pass metabolism - Physiologically implausible for most drugs *6770 mL/min* - This clearance is **physiologically impossible** as it exceeds cardiac output (5-6 L/min = 5000-6000 mL/min) [3] - Clearance cannot exceed the blood flow to the eliminating organ [3] - Clearly a distracter option with no pharmacokinetic validity

Q: Which statement best describes the relationship between drug potency and efficacy in dose-response curves?

Drug B is the most efficacious. ***Drug B is the most efficacious*** - **Efficacy** refers to the **maximum effect (Emax)** a drug can produce, represented by the plateau height of the dose-response curve on the y-axis - **Drug B's curve reaches the highest point**, indicating it produces the greatest maximal blocking effect (~100 units) - **This makes Drug B the most efficacious drug** among the three, as it can produce the largest therapeutic response regardless of how much drug is given - Efficacy order: Drug B > Drug C > Drug D *Drug C is the most potent* - **Potency** refers to the amount of drug needed to produce a given effect, measured by **EC50** (the concentration producing 50% of maximal effect) - **The lower the EC50, the more potent the drug** (curve shifted to the left) - **Drug B has the lowest EC50** (its curve is furthest to the left), making it the most potent drug, not Drug C - Drug C requires a higher concentration than Drug B to achieve 50% effect, so it is less potent - Potency order: Drug B > Drug C > Drug D *Drug C is as efficacious as drug D* - **Drug C has higher efficacy than Drug D** because its curve reaches a higher plateau on the y-axis - Drug C achieves a maximal blocking effect of approximately 100 units, while Drug D reaches only approximately 75 units - **Different efficacy values** mean they are not equally efficacious - A drug's efficacy is independent of the dose required and depends only on the maximum achievable effect *Drug D is more potent than drug C* - **Drug C is actually more potent than Drug D**, not the reverse - Drug C's dose-response curve is **shifted to the left** of Drug D's curve, indicating a lower EC50 - This means **Drug C requires a lower concentration** to achieve 50% of its maximal effect compared to Drug D - The leftward shift indicates greater potency for Drug C

Q: Loading dose of an oral drug depends on all of the following except?

Half-life. ***Correct Answer: Half-life*** - **Half-life** primarily determines the **maintenance dose** and **dosing interval**, not the loading dose - The **loading dose (LD)** is calculated to rapidly achieve the desired therapeutic **plasma concentration** using the formula: **LD = (Cp × Vd) / F** - Half-life determines how long it takes to reach steady state (4-5 half-lives) and how frequently maintenance doses should be given - The loading dose bypasses the waiting time by immediately achieving therapeutic levels *Incorrect: Volume of distribution* - **Vd** is a mandatory parameter in the calculation of the loading dose formula - It determines how widely the drug distributes in the body relative to the target plasma concentration - A higher **Vd** necessitates a higher loading dose to saturate tissue binding sites and achieve therapeutic plasma levels quickly *Incorrect: Plasma concentration* - The loading dose is specifically calculated to quickly achieve the desired therapeutic **steady-state plasma concentration (Cp)** - The target concentration (Cp) is central to the loading dose calculation and appears in the numerator of the formula - The goal of the loading dose is to bypass the time required to reach this concentration with maintenance doses alone *Incorrect: Bioavailability* - **Bioavailability (F)** represents the fraction of the administered drug that reaches systemic circulation - It is crucial for oral drugs where absorption may be incomplete due to first-pass metabolism or incomplete absorption - The loading dose formula includes **F** in the denominator (LD = (Cp × Vd) / F) to adjust for incomplete absorption

Q: The effect of both drugs given together on the blood pressure of a patient was evaluated in comparison with the effect of individual drugs on BP. The following curve represents: (Recent NEET Pattern 2016-17)

Synergism. ***Synergism*** - The graph shows that the effect of drugs A and B when given together (A+B) is significantly **greater than the sum of their individual effects**. - This amplified effect, where the combined response is more than the simple addition of individual responses, is the definition of **synergism** (also called potentiation or supra-additive effect). *Summation* - Summation occurs when the **combined effect** of two drugs is **equal to the arithmetic sum** of their individual effects. - In the depicted graph, the peak effect of A+B is clearly much higher than the sum of the peaks of A and B individually, ruling out simple summation. *Additive effects* - Additive effects are synonymous with summation, meaning the combined effect is precisely the sum of individual effects. - The graph demonstrates a response that **exceeds a simple additive effect**, indicating a synergistic interaction rather than mere additive action. *Antagonism* - **Antagonism** occurs when one drug reduces or blocks the effect of another drug, resulting in a combined effect that is **less than the sum** of individual effects. - In the depicted graph, the combined effect (A+B) clearly shows enhancement rather than reduction, ruling out antagonism.

Q: A new sedative-hypnotic drug is being evaluated in preclinical toxicity studies. The following quantal dose-response curve is obtained showing the hypnotic effect and lethal effect. Calculate the therapeutic index of the drug being tested.

1.8. The image shows a **quantal dose-response curve** depicting the percentage of subjects responding to increasing doses for two effects: **hypnosis** (therapeutic effect) and **death** (toxic effect). The **Therapeutic Index (TI)** is calculated as **TI = LD50/ED50**. **Steps to calculate:** 1. **Determine ED50 for Hypnosis** (therapeutic effect): - Locate 50% response on the Y-axis - Trace horizontally to intersect the "Hypnosis" curve - Trace vertically down to the X-axis (log dose) - ED50 ≈ **2.5** on the log dose scale 2. **Determine LD50 for Death** (toxic effect): - Locate 50% response on the Y-axis - Trace horizontally to intersect the "Death" curve - Trace vertically down to the X-axis (log dose) - LD50 ≈ **4.5** on the log dose scale 3. **Calculate Therapeutic Index:** - **TI = LD50 / ED50 = 4.5 / 2.5 = 1.8** ***Correct Option: 1.8*** - This is the correct therapeutic index calculated from the ratio of LD50 to ED50 - A TI of 1.8 indicates a relatively narrow margin of safety between therapeutic and lethal doses - Higher TI values indicate safer drugs *Incorrect Option: 0.56* - This would be the reciprocal calculation (ED50/LD50), which is not how TI is defined - TI is always LD50/ED50, not the reverse *Incorrect Option: 2.5* - This is the ED50 value (effective dose for hypnosis), not the therapeutic index - This represents only one component of the TI calculation *Incorrect Option: 4.5* - This is the LD50 value (lethal dose), not the therapeutic index - This represents only the numerator in the TI calculation

Question 1

A highly ionized drug is characterized by which of the following properties?

Accepted Answer

It is excreted mainly by the kidney.

Answer

It can cross the placental barrier easily.

Answer

It is well absorbed from the intestine.

Answer

It accumulates in cellular lipids.

Question 2

A three-year-old child is brought to the emergency department having just ingested a large overdose of an antihistaminic drug. This drug is a weak base capable of entering most tissues, including the brain. On physical examination, the heart rate is 100/minute, blood pressure is 110/60 mm Hg, and the respiratory rate is 20/minute. In this case of poisoning, which of the following is true regarding the management?

Accepted Answer

Urinary excretion would be accelerated by administration of NH4Cl, an acidifying agent.

Answer

Urinary excretion would be accelerated by administration of NaHCO3, an alkalinizing agent.

Answer

More of the drug would be ionized at blood pH than at stomach pH.

Answer

Absorption of the drug would be faster from the stomach than from the small intestine.

Question 3

A volunteer is to receive a new drug in a phase I clinical trial. The clearance and the volume of distribution of the drug in the volunteer are 1.386 L/hr and 80 L respectively. What would be the approximate half-life of the drug?

Accepted Answer

40 hr

Answer

83 hr

Answer

77 hr

Answer

0.02 hr

Question 4

The redistribution phenomenon is observed in which of the following drugs?

Accepted Answer

Thiopentone

Answer

Halothane

Answer

Ether

Answer

All of the above

Question 5

Which of the following statements about biotransformation is NOT true?

Accepted Answer

Conversion of polar to less polar compounds

Answer

Active metabolite generation

Answer

Conversion of less polar to more polar compounds

Answer

Generation of active drug from a prodrug

Question 6

A 75 kg person is administered a drug with a half-life of 3 hours. What is the approximate clearance of the drug?

Accepted Answer

23 mL/min

Answer

6770 mL/min

Answer

1670 mL/min

Answer

210 mL/min

Question 7

Which statement best describes the relationship between drug potency and efficacy in dose-response curves?

Accepted Answer

Drug B is the most efficacious

Answer

Drug C is as efficacious as drug D

Answer

Drug D is more potent than drug C

Answer

Drug C is the most potent

Question 8

Loading dose of an oral drug depends on all of the following except?

Accepted Answer

Half-life

Answer

Volume of distribution

Answer

Plasma concentration

Answer

Bioavailability

Question 9

The effect of both drugs given together on the blood pressure of a patient was evaluated in comparison with the effect of individual drugs on BP. The following curve represents: (Recent NEET Pattern 2016-17)

Accepted Answer

Synergism

Answer

Summation

Answer

Additive effects

Answer

Antagonism

Question 10

A new sedative-hypnotic drug is being evaluated in preclinical toxicity studies. The following quantal dose-response curve is obtained showing the hypnotic effect and lethal effect. Calculate the therapeutic index of the drug being tested.

Accepted Answer

1.8

Answer

4.5

Answer

2.5

Answer

0.56

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?